Brochure More information from http://www.researchandmarkets.com/reports/2152222/ Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Description: Xarelto (Atrial Fibrillation) Analysis and Forecasts to 2022 Summary GlobalData s pharmaceuticals report, Xarelto (Atrial Fibrillation) Analysis and Forecasts to 2022 provides Xarelto global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData s proprietary databases, primary and secondary research using Company s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. Scope - Therapy area profile including patient population for the US, EU5 and Japan (seven major markets) - Analysis and review of Xarelto including sales data - Qualitative and quantitative assessment of market space - Analysis of the trends, drivers and restraints shaping and defining the markets - In-depth analysis of Xarelto including efficacy, safety, pricing, competition and other details which influence its sales potential - Global sales forecast for 2011-2022 for Xarelto Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of competition by understanding the changing competitive landscape - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of the drug s performance - Examine the historical sales performance of a drug in seven major markets - Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets Keywords Xarelto, rivaroxaban, anticoagulant, direct factor Xa inhibitor, prevention of stroke and systemic embolism, non-valvular atrial fibrillation, deep vein thrombosis, venousthromboembolism Contents: 1 1 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Atrial Fibrillation Market 2.2 Epidemiology 2.3 Etiology and Risk Factors 2.3.1 Symptoms associated with AF 2.4 GlobalData Analysis and Forecasts Report Guidance 3 Atrial Fibrillation: Market Characterization 3.1 Atrial Fibrillation Market 3.2 Atrial Fibrillation Market Forecasts and CAGR 3.3 Drivers of Atrial Fibrillation Market 3.3.1 High Unmet need 3.3.2 Strong Pipeline
3.3.3 Increase in prevalence and ageing populations 3.3.4 Organisation of Awareness Campaigns 3.4 Barriers in Atrial Fibrillation Market 3.4.1 Limitations in established therapies 3.4.2 High cost of emerging therapies 4 Classification in Atrial Fibrillation: Introduction 4.1 AF Classification 4.1.1 Pathophysiology of AF 4.1.2 Diagnosis in Atrial Fibrillation 4.1.3 Impact of Atrial Fibrillation 5 Treatment Options and Management in Atrial Fibrillation 5.1 Rate control and Rhythm control 5.2 Rate Control Versus Rhythm Control 6 Xarelto 6.1 Introduction 6.2 Mechanism of Action 6.3 Clinical Studies 6.4 Approval Status of Xarelto 6.5 Factors Affecting Sales of Xarelto 6.5.1 Non-inferior to warfarin 6.5.2 Convenient dosing schedule 6.5.3 Rebound Effect of Xarelto 6.6 Drug Evaluation 6.6.1 Drug Risk Benefit Score 6.6.2 Intensity of Competition 6.7 Sales Forecast 6.7.1 Target Patient Pool of Xarelto 6.7.2 Dosing 6.7.3 Market Penetration 6.7.4 Annual Cost of Therapy 6.7.5 Global Sales Projections of Xarelto 7 Appendix 7.1 Market Definitions 7.2 Abbreviations 7.3 Research Methodology 7.3.1 Coverage 7.3.2 Secondary Research 7.3.3 Forecasting 7.3.4 Number of Patients Approved to Take the Drug 7.3.5 Net Penetration of Drug 7.3.6 Net Annual Dosing 7.3.7 Annual Cost of Therapy 7.4 Drug Sales Estimates Model 7.5 Contact Us 7.6 Disclaimer 7.7 Sources 1.1 List of Tables Table 1: Epidemiology of Atrial Fibrillation (2011) Table 2: Increase in the Risk of AF in The Presence of Risk Factors Table 3: Stratification of All Risk Factors For Atrial Fibrillation Table 4: Atrial Fibrillation Classification Table 5: Treatment Guidelines For the Management of Atrial Fibrillation Table 6: Xarelto, Phase III Clinical Trial Results Table 7: Xarelto Approval status Table 8: Drug Risk Benefit Score of Xarelto Table 9: Xarelto, Atrial Fibrillation, Global, Annual Cost of Therapy ($), 2011 Table 10: Xarelto, Atrial Fibrillation, Global, Sales Estimates ($m), 2011 2022 Table 11: Xarelto, Atrial Fibrillation, The US, Sales Estimates ($m), 2011 2022 Table 12: Xarelto, Atrial Fibrillation, The UK, Sales Estimates ($m), 2011 2022 Table 13: Xarelto, Atrial Fibrillation, France, Sales Estimates ($m), 2011 2022 Table 14: Xarelto, Atrial Fibrillation, Germany, Sales Estimates ($m), 2011 2022 Table 15: Xarelto, Atrial Fibrillation, Italy, Sales Estimates ($m), 2011 2022
Table 16: Xarelto, Atrial Fibrillation, Spain, Sales Estimates ($m), 2011 2022 Table 17: Xarelto, Atrial Fibrillation, Japan, Sales Estimates ($m), 2012 2022 1.2 List of Figures Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011 2022 Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation Figure 3: Increase of Prevalance Population in Atrial Fibrillation Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation Figure 5: Broad classification of Patterns in Atrial Fibrillation Figure 6: Disease States Associated with Atrial Fibrillation, By (%) Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF) Figure 8: Management of Newly Discovered Atrial Fibrillation (AF) Figure 9: Drug Model Diagram of Xarelto Figure 10: Xarelto, Atrial Fibrillation, Global, Sales Estimates ($m), 2011 2022 Figure 11: Xarelto, Atrial Fibrillation, The US, Sales Estimates ($m), 2011 2022 Figure 12: Xarelto, Atrial Fibrillation, The UK, Sales Estimates ($m), 2011 2022 Figure 13: Xarelto, Atrial Fibrillation, France, Sales Estimates ($m), 2011 2022 Figure 14: Xarelto, Atrial Fibrillation, Germany, Sales Estimates ($m), 2011 2022 Figure 15: Xarelto, Atrial Fibrillation, Italy, Sales Estimates ($m), 2011 2022 Figure 16: Xarelto, Atrial Fibrillation, Spain, Sales Estimates ($m), 2011 2022 Figure 17: Xarelto, Atrial Fibrillation, Japan, Sales Estimates ($m), 2012 2022 Figure 18: Xarelto, Atrial Fibrillation, Global, Sales Distribution, By Country( %), 2021 Figure 19: Patients Approved for the Drug Ordering: Order Online - http://www.researchandmarkets.com/reports/2152222/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: http://www.researchandmarkets.com/reports/2152222/ SC Site License: Single User: Enterprisewide: Quantity USD 4000 USD 2000 USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World